| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.96 | 27.3% |
| Total Income | 0.96 | 27.3% |
| Expenditure | 4.52 | 37.4% |
| PBT | — | |
| Net Profit | -3.56 | 82.6% |
| OPM | — | |
| NPM | — | |
| EPS | -0.52 | 62.6% |
Ensysce Biosciences Reports Q1 2026 Financial Results
16 May 2026 · 16 May, 2:03 am
Summary
Ensysce Biosciences reported its financial and operational results for the first quarter ended March 31, 2026. The company highlighted achieving 50% of the interim enrollment target in its pivotal PF614-301 Phase 3 trial and the publication of peer-reviewed clinical data validating its MPAR® overdose-protection technology. R&D expenses increased to $3.3 million due to Phase 3 clinical trial activity for PF614. The company's cash and cash equivalents were $0.7 million as of March 31, 2026, with a subsequent $2.0 million financing tranche closed in April 2026.
Key Highlights
- 1
Ensysce Biosciences reported financial and operational results for the first quarter ended March 31, 2026.
- 2
The company achieved 50% of the interim enrollment target in its pivotal PF614-301 Phase 3 trial.
- 3
Clinical peer-reviewed data was published validating the MPAR® overdose-protection technology.
- 4
The company expanded its patent estate across both its opioid and ADHD programs.
- 5
Following quarter-end, IRB approval was secured to initiate Part 3 of PF614-MPAR-102.
- 6
Federal grants totaled $1.0 million for the first quarter of 2026.
- 7
Research & Development expenses increased by $1.4 million to $3.3 million for the first quarter of 2026.
Management Comments
Lynn Kirkpatrick
“The first quarter of 2026 delivered meaningful operational and clinical momentum across our pipeline, underscoring the strength of our strategy and the discipline of our execution,” Dr. Kirkpatrick continued, “Following quarter-end, we closed a second financing tranche under an existing facility and secured IRB approval to initiate Part 3 of PF614-MPAR-102, the final stage of that study. Advancing this program strengthens the clinical evidence supporting a product we believe can fundamentally reshape how overdose risk is managed. In parallel, our Board has initiated a formal review of strategic alternatives, including potential partnerships and licensing opportunities, to accelerate the development of our TAAP™ and MPAR® platforms and unlock additional shareholder value.”
Informational and educational content only. Not investment advice.